ID   PEA2
AC   CVCL_2683
DR   cancercelllines; CVCL_2683
DR   CancerTools; 151679
DR   Cell_Model_Passport; SIDM01425
DR   ECACC; 10032307
DR   GEO; GSM459852
DR   GEO; GSM659401
DR   GEO; GSM2474997
DR   GEO; GSM4973220
DR   GEO; GSM4973226
DR   GEO; GSM4973232
DR   GEO; GSM4973238
DR   GEO; GSM4973244
DR   GEO; GSM4973250
DR   GEO; GSM4973256
DR   GEO; GSM4973262
DR   GEO; GSM4973268
DR   PRIDE; PXD020764
DR   Progenetix; CVCL_2683
DR   Wikidata; Q54946893
DR   Ximbio; 151679
RX   PubMed=3167863;
RX   PubMed=20581869;
RX   PubMed=22183581;
RX   PubMed=23415752;
RX   PubMed=25230021;
RX   PubMed=28196595;
RX   PubMed=28273451;
RX   PubMed=30485824;
RX   PubMed=35028612;
WW   Info; MCLP; -; https://tcpaportal.org/mclp/
CC   Part of: MD Anderson Cell Lines Project.
CC   Part of: OCCP ovarian cancer cell line panel.
CC   Doubling time: 66 hours (PubMed=3167863).
CC   Sequence variation: Mutation; HGNC; HGNC:952; BARD1; Simple; p.Trp218Ter (c.653G>A); ClinVar=VCV000482781; Zygosity=Unspecified (PubMed=25230021).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Cys242Alafs*5 (c.723delC) (p.S241fs); ClinVar=VCV001074338; Zygosity=Unspecified (PubMed=25230021).
CC   Omics: Genomics; Whole genome sequencing.
CC   Omics: Proteomics.
CC   Omics: Proteomics; Expression; Reverse-phase protein array.
CC   Omics: Transcriptomics; RNAseq.
CC   Omics: Variations; SNP array analysis.
CC   Discontinued: ECACC; 10032307; true.
CC   Derived from site: Metastatic; Ascites; UBERON=UBERON_0007795.
ST   Source(s): ECACC=10032307; PubMed=22183581; PubMed=25230021; PubMed=30485824
ST   Amelogenin: X
ST   CSF1PO: 11,14
ST   D13S317: 8
ST   D16S539: 12,13
ST   D18S51: 17
ST   D19S433: 12,13
ST   D21S11: 30
ST   D2S1338: 19
ST   D3S1358: 16
ST   D5S818: 11,13
ST   D7S820: 10,12
ST   D8S1179: 14
ST   FGA: 25
ST   Penta D: 13,15
ST   Penta E: 7,13
ST   TH01: 9
ST   TPOX: 8 (ECACC=10032307)
ST   TPOX: 8,12 (PubMed=22183581; PubMed=25230021; PubMed=30485824)
ST   vWA: 17,18
DI   NCIt; C5228; Ovarian cystadenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_2682 ! PEA1
SX   Female
AG   Age unspecified
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 10-04-25; Version: 29
//
RX   PubMed=30485824; DOI=10.1016/j.celrep.2018.10.096; PMCID=PMC6481945;
RA   Papp, Eniko
RA   Hallberg, Dorothy
RA   Konecny, Gottfried E.
RA   Bruhm, Daniel C.
RA   Adleff, Vilmos
RA   Noe, Michael
RA   Kagiampakis, Ioannis
RA   Palsgrove, Doreen
RA   Conklin, Dylan
RA   Kinose, Yasuto
RA   White, James R.
RA   Press, Michael Frederick
RA   Drapkin, Ronny I.
RA   Easwaran, Hariharan
RA   Baylin, Stephen Bruce
RA   Slamon, Dennis Joseph
RA   Velculescu, Victor E.
RA   Scharpf, Robert B.
RT   "Integrated genomic, epigenomic, and expression analyses of ovarian
RT   cancer cell lines.";
RL   Cell Rep. 25:2617-2633(2018).
//
RX   PubMed=35028612; DOI=10.1016/j.xcrm.2021.100471; PMCID=PMC8714940;
RA   Huang, Dong-Qing
RA   Chowdhury, Shrabanti
RA   Wang, Hong
RA   Savage, Sara R.
RA   Ivey, Richard G.
RA   Kennedy, Jacob J.
RA   Whiteaker, Jeffrey R.
RA   Lin, Chen-Wei
RA   Hou, Xiao-Nan
RA   Oberg, Ann L.
RA   Larson, Melissa C.
RA   Eskandari, Najmeh
RA   Delisi, Davide A.
RA   Gentile, Saverio
RA   Huntoon, Catherine J.
RA   Voytovich, Uliana J.
RA   Shire, Zahra J.
RA   Yu, Qing
RA   Gygi, Steven P.
RA   Hoofnagle, Andrew Norbert
RA   Herbert, Zachary T.
RA   Lorentzen, Travis D.
RA   Calinawan, Anna
RA   Karnitz, Larry M.
RA   Weroha, S. John
RA   Kaufmann, Scott H.
RA   Zhang, Bing
RA   Wang, Pei
RA   Birrer, Michael J.
RA   Paulovich, Amanda Grace
RT   "Multiomic analysis identifies CPT1A as a potential therapeutic target
RT   in platinum-refractory, high-grade serous ovarian cancer.";
RL   Cell Rep. Med. 2:100471.1-100471.32(2021).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005; PMCID=PMC5501076;
RA   Li, Jun
RA   Zhao, Wei
RA   Akbani, Rehan
RA   Liu, Wen-Bin
RA   Ju, Zhen-Lin
RA   Ling, Shi-Yun
RA   Vellano, Christopher P.
RA   Roebuck, Paul
RA   Yu, Qing-Hua
RA   Eterovic, Agda Karina
RA   Byers, Lauren Averett
RA   Davies, Michael A.
RA   Deng, Wan-Leng
RA   Gopal, Y.N. Vashisht
RA   Chen, Guo
RA   von Euw, Erika Maria
RA   Slamon, Dennis Joseph
RA   Conklin, Dylan
RA   Heymach, John Victor
RA   Gazdar, Adi F.
RA   Minna, John D.
RA   Myers, Jeffrey N.
RA   Lu, Yi-Ling
RA   Mills, Gordon B.
RA   Liang, Han
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=25230021; DOI=10.1371/journal.pone.0103988; PMCID=PMC4167545;
RA   Beaufort, Corine M.
RA   Helmijr, Jean C.A.
RA   Piskorz, Anna M.
RA   Hoogstraat, Marlous
RA   Ruigrok-Ritstier, Kirsten
RA   Besselink, Nicolle
RA   Murtaza, Muhammed
RA   van IJcken, Wilfred F.J.
RA   Heine, Anouk A.J.
RA   Smid, Marcel
RA   Koudijs, Marco J.
RA   Brenton, James D.
RA   Berns, Els M.J.J.
RA   Helleman, Jozien
RT   "Ovarian cancer cell line panel (OCCP): clinical importance of in
RT   vitro morphological subtypes.";
RL   PLoS ONE 9:e103988.1-e103988.16(2014).
//
RX   PubMed=3167863;
RA   Langdon, Simon P.
RA   Lawrie, Sandra S.
RA   Hay, Frances G.
RA   Hawkes, Mary M.
RA   McDonald, Amanda
RA   Hayward, Ian P.
RA   Schol, Dick J.
RA   Hilgers, Jo
RA   Leonard, Robert C.F.
RA   Smyth, John Fletcher
RT   "Characterization and properties of nine human ovarian adenocarcinoma
RT   cell lines.";
RL   Cancer Res. 48:6166-6172(1988).
//
RX   PubMed=20581869; DOI=10.1038/onc.2010.245; PMCID=PMC2933510;
RA   Cooke, Susanna L.
RA   Ng, Charlotte Kiu Yan
RA   Melnyk, Nataliya
RA   Garcia, Maria J.
RA   Hardcastle, Thomas James
RA   Temple, Jillian
RA   Langdon, Simon P.
RA   Huntsman, David G.
RA   Brenton, James D.
RT   "Genomic analysis of genetic heterogeneity and evolution in high-grade
RT   serous ovarian carcinoma.";
RL   Oncogene 29:4905-4913(2010).
//
RX   PubMed=23415752; DOI=10.1016/j.molonc.2012.12.007; PMCID=PMC4106023;
RA   Stordal, Britta
RA   Timms, Kirsten
RA   Farrelly, Angela
RA   Gallagher, Danielle
RA   Busschots, Steven
RA   Renaud, Mickael
RA   Thery, Julien
RA   Williams, Deborah
RA   Potter, Jennifer
RA   Tran, Thanh
RA   Korpanty, Greg
RA   Cremona, Mattia
RA   Carey, Mark S.
RA   Li, Jie
RA   Li, Yang
RA   Aslan, Ozlem
RA   O'Leary, John J.
RA   Mills, Gordon B.
RA   Hennessy, Bryan T.
RT   "BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one
RT   functionally deleterious BRCA1 mutation.";
RL   Mol. Oncol. 7:567-579(2013).
//
RX   PubMed=22183581; DOI=10.1002/path.3980;
RA   Ng, Charlotte Kiu Yan
RA   Cooke, Susanna L.
RA   Howe, Kevin L.
RA   Newman, Scott
RA   Xian, Jian
RA   Temple, Jillian
RA   Batty, Elizabeth M.
RA   Pole, Jessica C.M.
RA   Langdon, Simon P.
RA   Edwards, Paul A.W.
RA   Brenton, James D.
RT   "The role of tandem duplicator phenotype in tumour evolution in
RT   high-grade serous ovarian cancer.";
RL   J. Pathol. 226:703-712(2012).
//
RX   PubMed=28273451; DOI=10.1016/j.celrep.2017.02.028;
RA   Medrano, Mauricio
RA   Communal, Laudine
RA   Brown, Kevin R.
RA   Iwanicki, Marcin
RA   Normand, Josee
RA   Paterson, Joshua
RA   Sircoulomb, Fabrice
RA   Krzyzanowski, Paul M.
RA   Novak, Marian
RA   Doodnauth, Sasha A.
RA   Suarez Saiz, Fernando Jose
RA   Cullis, Jane
RA   Al-awar, Rima
RA   Neel, Benjamin G.
RA   McPherson, John
RA   Drapkin, Ronny I.
RA   Ailles, Laurie
RA   Mes-Masson, Anne-Marie
RA   Rottapel, Robert
RT   "Interrogation of functional cell-surface markers identifies CD151
RT   dependency in high-grade serous ovarian cancer.";
RL   Cell Rep. 18:2343-2358(2017).
//